Protected by US Patents
Targeting splicing factors
ESH eLearning, Timothy Graubert,
366603
Panel discussion
ESH eLearning, Faculty / Presenters,
366602
Initiation and progression of CALR mutant MPN
ESH eLearning, Ann Mullally,
366601
CALR mutations in the development of MPN using mouse modeling
ESH eLearning, Caroline Marty,
366600
Panel discussion
ESH eLearning, Faculty / Presenters,
366599
Expression of CD47 and Calr in Myeloproliferative Neoplasms: Potential New Therapeutical Targets
ESH eLearning, Ciro Rinaldi,
366598
Therapy of overlap MPN/MDS syndromes
ESH eLearning, Lionel Adès,
366597
Why Hydroxyurea must still be the standard in patients with Essential Thrombocythemia
ESH eLearning, Tiziano Barbui,
366596
Insights in diagnosis and management of CMML
ESH eLearning, Eric Solary,
366595
Panel discussion
ESH eLearning, Faculty / Presenters,
366594
Prognostic scores in MPN
ESH eLearning, Alessandro Vannucchi,
366593
Keynote lecture: Combination therapies for myelofibrosis
ESH eLearning, Ruben Mesa,
366592
Panel discussion
ESH eLearning, Faculty / Presenters,
366591
Therapeutic approaches in post-MPN AML
ESH eLearning, John Mascarenhas,
366589
Unusual firms of eosinophilias (FGFR1 inhibitors, MoAb for other eosinophilias)
ESH eLearning, Andreas Reiter,
366588
Panel Discussion
ESH eLearning, Faculty / Presenters,
366587
Keynote lecture: New Insights into the role of JAK2V617F in MPN pathogenesis
ESH eLearning, Ross Levine,
366586
Panel Discussion
ESH eLearning, Faculty / Presenters,
366584
HMGA1 Chromatin Regulators Induce Transcriptional Networks Involved in Cell Fate and Proliferation during MPN Progression
ESH eLearning, Linda Resar,
366583
Non-genetic mechanisms of clonal expansion
ESH eLearning, David Kent,
366582
Role of inflammation in MPN initiation and progression
ESH eLearning, Angela Fleischman,
366581
Single cell studies to uncover novel insights into MPN pathogenesis
ESH eLearning, Adam Mead,
366580
Panel Discussion
ESH eLearning, Faculty / Presenters,
366579
Molecular pathogenesis of progression from MPN to AML
ESH eLearning, Raajit Rampal,
366578
MPN stem/cell directed therapeutics
ESH eLearning, Ronald Hoffman,
366577
Panel discussion
ESH eLearning, Faculty / Presenters,
366512
New EU regulations for clinical trials
ESH eLearning, Joanna Wilinska- Mackowiak,
366511
APR 246, Magorlimab and other potential drugs active in MDS/AML with TP53 mutation
ESH eLearning, Thomas Cluzeau,
366510
Rethinking clinical trial endpoints in MDS
ESH eLearning, Mikkael Sekeres,
366509
Panel discussion
ESH eLearning, Faculty / Presenters,
366508
Clinical trials - German MDS study group / EMSCO
ESH eLearning, Silke Gloaguen,
366507
GFM
ESH eLearning, Pierre Fenaux,
366506
GESMD clinical trials and projects
ESH eLearning, María Díez Campelo,
366505
Ongoing MDS Studies in Italy
ESH eLearning, Valeria Santini,
366504
Introduction
ESH eLearning, Raphael Itzykson,
366503
Discussion
ESH eLearning, Faculty / Presenters,
366502
Keynote lecture : routine integration of molecular data in the prognostic stratification: the IPSS molecular
ESH eLearning, Elsa Bernard,
366501
Panel discussion
ESH eLearning, Faculty / Presenters,
366500
Novel strategies to treat cytopenia in low risk MDS
ESH eLearning, Uwe Platzbecker,
366499
A renewed role for intensive chemotherapy ?
ESH eLearning, Thomas Cluzeau,
366498
Higher risk MDS: lessons from elderly AML
ESH eLearning, Lionel Adès,
366497
Strategies to improve HMA based therapy
ESH eLearning, Pierre Fenaux,
366496
Panel discussion
ESH eLearning, Faculty / Presenters,
366495
Overview of novel therapeutics in MDS: lessons from the lab
ESH eLearning, Valeria Santini,
366494
Current treatment guidelines for CMML and rare subtypes
ESH eLearning, Raphael Itzykson,
366493
Allo transplantation: when and how?
ESH eLearning, Marie Robin,
366492
HMAs: when and how
ESH eLearning, Mikkael Sekeres,
366491
Panel discussion
ESH eLearning, Faculty / Presenters,
366490
How to best define del (5q)
ESH eLearning, María Díez Campelo,
366489
Why and how should we target mature cells of the clone in chronic myelomonocytic leukemia
ESH eLearning, Eric Solary,
366488
Panel discussion
ESH eLearning, Faculty / Presenters,
366487
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk Myelodysplastic Syndrome (MDS): A Retrospective Analysis from the Grupo Español De Síndromes Mielodisplásicos (GESMD) Spanish MDS Registry
ESH eLearning, María Díez Campelo,
366486
The best soup has many ingredients: prognosis in MDS combining clinical and biologic information
ESH eLearning, Jaroslaw Maciejewski,
366485
The best clinical prognostic system for MDS is…
ESH eLearning, Rami S. Komrokji,
366484
The basics are not enough: how molecular genetics make the difference of MDS
ESH eLearning, Torsten Haferlach,
366483
Panel discussion
ESH eLearning, Faculty / Presenters,
366482
Artificial intelligence for treatment and prognosis
ESH eLearning, Anne Sophie Kubasch,
366481
Panel discussion
ESH eLearning, Faculty / Presenters,
366480
The case of iron
ESH eLearning, Valeria Santini,
366479
Impact of the microbiome on hematopoiesis
ESH eLearning, Katherine King,
366478
The immunome
ESH eLearning, Shahram Kordasti,
366477
Panel discussion
ESH eLearning, Faculty / Presenters,
366476
Clonal Cytopenia of Undetermined Significance
ESH eLearning, Luca Malcovati,
366475
CHIP: Clonal hematopoiesis of not-so-indeterminate potential
ESH eLearning, Klaus Metzeler,
366474
Panel discussion
ESH eLearning, Faculty / Presenters,
366473
Brief oral communication
ESH eLearning, Vi Lam,
366472
CAR-T cell therapy in CLL
ESH eLearning, Tanya Siddiqi,
366471
MAPK/ERK
ESH eLearning, Jennifer Brown,
366470
Panel discussion
ESH eLearning, Faculty / Presenters,
366469
Brief oral communication
ESH eLearning, Arnon Kater,
366468
CAR-T cell immunotherapy for CLL: a chance for cure in the era of small molecules?
ESH eLearning, Marco Ruella,
366467
Future of PI3Ks
ESH eLearning, John G. Gribben,
366466
Panel discussion
ESH eLearning, Faculty / Presenters,
366465
Brief oral communication
ESH eLearning, Kristyna Zavacka,
366464
Non-covalent BTK inhibitors (ARQ531 / MK1026; pirtobrutinib)
ESH eLearning, Anthony Mato,
366463
Resistance to covalent BTK inhibitors
ESH eLearning, Adrian Wiestner,
366462
Panel discussion
ESH eLearning, Faculty / Presenters,
366461
Zanubrutinib and combinations
ESH eLearning, Alessandra Tedeschi,
366460
Acalabrutinib and combinations
ESH eLearning, Richard Furman,
366459
Panel discussion
ESH eLearning, Faculty / Presenters,
366458
Brief oral communication
ESH eLearning, Fabrizio Mavilia,
366457
Defined duration vs MRD driven time-limited therapy
ESH eLearning, Talha Munir,
366456
BTK – BCL-2 combinations
ESH eLearning, John Allan,
366455
Venetoclax antibody combinations
ESH eLearning, Othman Al-Sawaf,
366454
Panel discussion
ESH eLearning, Faculty / Presenters,
366453
Brief oral communication
ESH eLearning, Emma Kennedy,
366452
Reversed microenvironmental stimuli; how CLL cells suppress T cell function
ESH eLearning, Arnon Kater,
366451
Effects of CXCR4- and macrophage-derived signals on the survival and growth of CLL cells
ESH eLearning, Dimitar Efremov,
366449
CD49d: a biologically relevant molecule and important prognostic marker in CLL
ESH eLearning, Chris Pepper,
366448
Panel discussion
ESH eLearning, Faculty / Presenters,
366447
Brief oral communication
ESH eLearning, Anna Andrzejczak,
366446
Prognostic role of rare gene mutations
ESH eLearning, Davide Rossi,
366445
IG mutational status and gene mutations
ESH eLearning, Richard Rosenquist Brandell,
366444
Panel discussion
ESH eLearning, Faculty / Presenters,
366443
Brief oral communication
ESH eLearning, Selena Mimmi,
366442
How do we look at MRD in 2021
ESH eLearning, Andrew Rawstron,
366441
Complex karyotype: what is relevant?
ESH eLearning, Panagiotis Baliakas,
366440
Low level TP53 clones: what is the significance?
ESH eLearning, Sarka Pospisilova,
366439
Panel discussion
ESH eLearning, Faculty / Presenters,
366438
Richter’s transformation
ESH eLearning, Silvia Deaglio,
366436